Guardant Health, Inc. GH
155.35 USD -3.44 (-2.17%)
At closeNov 10, 2026, 4:30 PM EST
155.35 0.00 0.00%
After hours · Nov 10, 4:30 PM ET
153.00 Day range 160.44
74.55 52-week range 191.05
- YTD
- +52.10%
- 1 year
- +58.65%
News
benzinga.com Piper Sandler Maintains Overweight on Guardant Health, Lowers Price Target to $190 Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and lowers the price target from $193 to $190.
businesswire.com Guardant Health to Participate in Upcoming Investor Conferences PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the following investor…
marketbeat.com What Guardant Health (GH) Said on Its Q3 Earnings Call Guardant Health NASDAQ: GH raised its full-year 2026 revenue forecast after third-quarter sales increased 36%, driven by growth in its oncology testing business and demand for its Shield blood-based…
zacks.com Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates Guardant Health (GH) came out with a quarterly loss of $0.29 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.39 per share a year ago.
zacks.com Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates The headline numbers for Guardant Health (GH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall…
benzinga.com Guardant Health Q3 2026 Earnings Call Transcript Guardant Health (NASDAQ:GH) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Guardant Health Raises FY2026 Sales Guidance from $1.340B-$1.360B to $1.360B-$1.370B vs $1.357B Est Guardant Health (NASDAQ:GH) raises FY2026 sales outlook from $1.340 billion-$1.360 billion to $1.360 billion-$1.370 billion vs $1.357 billion estimate.
benzinga.com Guardant Health Q3 Adj. EPS $(0.29) Beats $(0.32) Estimate, Sales $360.975M Beat $350.358M Estimate Guardant Health (NASDAQ:GH) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.32) by 9.38 percent. This is a 25.64 percent increase over losses of…
businesswire.com Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026. Third…
benzinga.com TwinStrand Biosciences Announces Confirmation Of U.S. Patent And Trademark Office Regarding Patentability Of All 23 Claims Of U.S. Patent Against Guardant Health TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing technology, today announced that the U.S. Patent and Trademark Office (USPTO) has confirmed the patentability of all 23 claims of…
zacks.com Countdown to Guardant Health (GH) Q3 Earnings: Wall Street Forecasts for Key Metrics Evaluate the expected performance of Guardant Health (GH) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key…
businesswire.com Kevin Sayer Joins Guardant Health Board of Directors PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is…
businesswire.com Guardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood Test PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced it received the 2026 Prix Galien USA Award for Best Medical Technology for…
zacks.com Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
businesswire.com Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, applauded the enactment of a new law (HB 1123) in Pennsylvania aligning insurance…
seekingalpha.com Allspring Emerging Growth Fund: Q3 2026 Top Contributors And Detractors After delivering results well above expectations, TWST management significantly raised its outlook and projected triple-digit growth in orders. During the quarter, LIFE shares performed well…- benzinga.com BTIG Maintains Buy on Guardant Health, Raises Price Target to $210 BTIG analyst Mark Massaro maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $195 to $210.
benzinga.com This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com This Guardant Health Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Analysts initiated coverage: VSE Sector Weight; Guardant, Quantum, Benitec and Diodes rated Buy/Overweight/Outperform with targets up to $200.
247wallst.com Here Are Friday’s Top Wall Street Analyst Research Calls: Deckers Outdoor, Globe Life, Guardant Health, Hess Midstream LP, Kimberly-Clark, Natera, NVR, SpaceX, Thermo Fisher Scientific, and More A wild Thursday saw Treasury yields crater, oil surge past $111, crypto liquidations top $431 million, and Meta's cash flow surprise rattle markets. Now analysts are reshuffling their calls on some…
benzinga.com Roth Capital Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $200 Roth Capital analyst Max Masucci initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $200.
defenseworld.net Guardant Health, Inc. (NASDAQ:GH) Stock Has Average Price Target of $190.00 Guardant Health, Inc. (NASDAQ: GH - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty-five ratings firms that are currently covering the stock, Marketbeat…
businesswire.com Guardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026 PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25…
marketbeat.com The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning Rate and energy headlines have kept the broad market jumpy, yet one sector keeps finding buyers. Healthcare has led on days when the S&P 500 slipped, and the Nasdaq Biotechnology Index has pushed to…
benzinga.com TwinStrand Biosciences Announces U.S. Patent And Trademark Office's Patent Trial And Appeal Board Rejects Guardant Health's Challenge To Core Patent Underlying Duplex Sequencing TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected…
zacks.com These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
gurufocus.com Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing
businesswire.com Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the…
defenseworld.net Reviewing The Pennant Group (NASDAQ:PNTG) and Guardant Health (NASDAQ:GH) Guardant Health (NASDAQ: GH - Get Free Report) and The Pennant Group (NASDAQ: PNTG - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two…- benzinga.com Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $200 Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $200.
- benzinga.com Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH Guardant360 CDx can now help identify cancer mutations earlier and drive improved patient outcomes in major global geographiesThis latest approval marks Guardant’s 31st CDx approval
benzinga.com Barclays Maintains Overweight on Guardant Health, Raises Price Target to $220 Barclays analyst Luke Sergott maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $200 to $220.
benzinga.com S&P 500, Nasdaq Hit Records, Power Stocks Rally on Google's Nuclear Deal: Stock Market Today S&P 500 and Nasdaq 100 hit records as the 10-year yield retreats from a 24-year high; Constellation Energy jumps on a Google nuclear deal.
benzinga.com Guardant Health Announces Results From Its COSMOS-MEL01 Trial Shows 81% Sensitivity For Distant Recurrence, 100% Post-Treatment Facility Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published…- benzinga.com Guggenheim Maintains Buy on Guardant Health, Raises Price Target to $200 Guggenheim analyst Subbu Nambi maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $190 to $200.
- benzinga.com Guardant Health’s Shield Blood Test For Colorectal Cancer Screening To Be Covered In EviCore By Evernorth Clinical Guidelines Effective January 1, 2027, Per ACS Guidelines Second largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholdersMilestone marks rapid…
- benzinga.com UBS Maintains Buy on Guardant Health, Raises Price Target to $225 UBS analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $175 to $225.
- benzinga.com Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203 Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.
benzinga.com Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.- benzinga.com Carelon Health Services To Cover Guardant Health’s Shield Blood Test Largest national medical benefit manager in the U.S. expands coverage for FDA-approved Shield blood test for colorectal cancer (CRC) screening to eligible policyholdersIncreasing total covered Shield…
benzinga.com Guardant Health Hit With Ongoing Royalties Over Duplex Sequencing Tech Guardant Health must pay TwinStrand Biosciences and the University of Washington over $245 million after a court finalized a patent dispute.- benzinga.com Piper Sandler Maintains Overweight on Guardant Health, Raises Price Target to $193 Piper Sandler analyst David Westenberg maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $135 to $193.
- benzinga.com Stephens & Co. Maintains Overweight on Guardant Health, Raises Price Target to $195 Stephens & Co. analyst Mason Carrico maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $170 to $195.
- benzinga.com Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $185 Morgan Stanley analyst Shannon O'Callaghan maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $175 to $185.
benzinga.com Stifel Maintains Buy on Guardant Health, Raises Price Target to $180 Stifel analyst Daniel Arias maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $130 to $180.- benzinga.com RBC Capital Maintains Outperform on Guardant Health, Raises Price Target to $200 RBC Capital analyst Dan Leonard maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $185 to $200.
- benzinga.com Mizuho Maintains Outperform on Guardant Health, Raises Price Target to $200 Mizuho analyst Anthony Petrone maintains Guardant Health (NASDAQ:GH) with a Outperform and raises the price target from $175 to $200.
- benzinga.com JP Morgan Maintains Overweight on Guardant Health, Raises Price Target to $195 JP Morgan analyst Casey Woodring maintains Guardant Health (NASDAQ:GH) with a Overweight and raises the price target from $185 to $195.
- benzinga.com TD Cowen Maintains Buy on Guardant Health, Raises Price Target to $210 TD Cowen analyst Dan Brennan maintains Guardant Health (NASDAQ:GH) with a Buy and raises the price target from $200 to $210.
benzinga.com AXT Posts Upbeat Q2 Earnings, Joins Newell Brands, SPX Technologies, Amazon And Other Big Stocks Moving Higher On Friday U.S. stocks mixed, Nasdaq up 50 pts. AXT Inc (NASDAQ: AXTI) rose 25.3% on strong Q2 results. Other gainers include NWL, FET, IESC, SPXC, AMZN, SPSC, DLB, GH, DXCM, and MPWR.